Free Webex Call
Global dementia and Alzheimer’s disease treatment market is expected to grow at impressive growth during the forecast period, 2024-2028. The increasing cases of Alzheimer's and dementia coupled with growing awareness regarding the diseases are bolstering the growth of the market. Moreover, elderly population are more prone to such diseases due to growing age, which in turn, is expected to positively impact the growth of market. Also, upsurge in R&D activities associated with disease, the introduction of new and innovative technologies and drugs, and increasing government initiatives such as investments, awareness programmes are expected to bolster the growth of market over the next few years. For instance, in 2022, a new initiative by McGill University’s Dementia Education Program received funding from the Public Health Agency of Canada to raise awareness of dementia and promote dementia-inclusive communities.Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The global dementia and Alzheimer’s disease treatment market is segmented into drug class, distribution channel, company and region. Based on drug class, the market is categorized into cholinergic/cholinesterase (ChE) inhibitors, memantine, and combination drugs. Out of these, the cholinergic/cholinesterase (ChE) inhibitor segment dominates the dementia and Alzheimer’s disease market. This is accredited to fact that it is first line of treatment for AD and most widely prescribed drug for the treatment. In addition, the drug is very effective for treating mild to severe dementia, which is contributing to the increasing growth of the segment.
The memantine segment is further expected to be the fastest growing segment during the forecast period. This is ascribed to its suitability in cholinergic/cholinesterase inhibitors intolerant patients suffering from AD.
Major players operating in the global dementia and Alzheimer’s disease treatment market include Merz Pharma GmbH & Co. KGaA, Novartis AG, Pfizer, Inc., Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd., AbbVie Inc., Eli Lilly and Company, and Corium, Inc. The companies are adopting new strategies in order to stay competitive in the market. Rising competitiveness is anticipated to drive innovation in the market, thereby helping the industry to solve existing challenges and meet the needs of the market.
Objective of the Study:
To analyze and estimate the market size of global dementia and Alzheimer’s disease treatment market from 2018 to 2021.To estimate and forecast the market size of global dementia and Alzheimer’s disease treatment market from 2022 to 2028 and growth rate until 2028.
To classify and forecast global dementia and Alzheimer’s disease treatment market based on drug class, distribution channel, company and regional distribution.
To identify dominant region or segment in the global dementia and Alzheimer’s disease treatment market.
To identify drivers and challenges for global dementia and Alzheimer’s disease treatment market.
To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global dementia and Alzheimer’s disease treatment market.
To conduct pricing analysis for global dementia and Alzheimer’s disease treatment market.
To identify and analyze the profile of leading players operating in global dementia and Alzheimer’s disease treatment market.
to identify key sustainable strategies adopted by market players in global dementia and Alzheimer’s disease treatment market.
The publisher performed both primary as well as exhaustive secondary research for this study. Initially, The research team sourced a list of companies across the globe. Subsequently, The research team conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the manufacturers which could not be identified due to the limitations of secondary research. The research team analyzed the hospitals and presence of all major players across the globe.
The publisher calculated the market size of global dementia and Alzheimer’s disease treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The research team sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.
Key Target Audience:
- Dementia and Alzheimer’s disease treatment facilities and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, forums and alliances related to dementia and Alzheimer’s disease treatment
Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.Report Scope:
In this report, global dementia and Alzheimer’s disease treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:Global Dementia and Alzheimer’s Disease Treatment Market, By Drug Class:
- Cholinergic/ Cholinesterase Inhibitors
- Donepezil
- Galantamine
- Rivastigmine
- Memantine
- Combination Drugs
- Memantine
- Donepezil
Global Dementia and Alzheimer’s Disease Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Dementia and Alzheimer’s Disease Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- South America
- Brazil
- Argentina
- Colombia
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global dementia and Alzheimer’s disease treatment market.Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs. The following customization options are available for the report:Company Information
Detailed analysis and profiling of additional market players (up to five).This product will be delivered within 1-3 business days.
Table of Contents
1. Product Overview
2. Research Methodology
3. Executive Summary
5. Clinical Trial Analysis
6. Global Dementia and Alzheimer’s Disease Treatment Market Outlook
7. Asia-Pacific Dementia and Alzheimer’s Disease Treatment Market Outlook
8. Europe Dementia and Alzheimer’s Disease Treatment Market Outlook
9. North America Dementia and Alzheimer’s Disease Treatment Market Outlook
10. South America Dementia and Alzheimer’s Disease Treatment Market Outlook
11. Middle East and Africa Dementia and Alzheimer’s Disease Treatment Market Outlook
12. Market Dynamics
14. Competitive Landscape
Companies Mentioned
- Merz Pharma GmbH & Co. KGaA
- Novartis AG
- Pfizer, Inc.
- Ono Pharmaceutical Co., Ltd.
- Johnson & Johnson Services, Inc.
- H. Lundbeck A/S
- F. Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Eli Lilly and Company
- Corium, Inc.
